Treating high-risk cervical cancer with chemoradiation and immunotherapy
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug called Cardenimumab combined with standard chemotherapy and radiation for women with high-risk cervical cancer. The goal is to see if adding this drug can improve outcomes for patients whose tumors are large, have spread to lymph nodes, or are stage IV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 74 with newly diagnosed cervical cancer that has not been treated before.
- Your cancer must be high-risk, meaning the tumor is larger than 5 cm, has spread to lymph nodes, or is stage IV.
- You are willing to receive chemotherapy and radiation together (called chemoradiation) as your main treatment.
- You have not had any prior cancer treatment like chemotherapy, radiation, immunotherapy, or targeted therapy.
- You are able to provide tumor tissue and blood samples for research, and complete quality-of-life surveys.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of chemotherapy and immunotherapy before standard chemoradiation for locally advanced cervical cancer. The goal is to see if adding immunotherapy first helps shrink the tumor and improve treatment outcomes.
This trial tests a new immunotherapy drug called cadonilimab combined with radiation therapy for people with locally advanced cervical cancer who cannot receive the usual chemotherapy due to age, kidney problems, heart issues, allergies, or personal choice.
This trial tests adding a new immunotherapy drug (cadonilimab) to standard chemotherapy before surgery for locally advanced cervical cancer. The goal is to see if this combination helps shrink the tumor more effectively before surgery.
This trial tests a new immunotherapy drug, cadonilimab, combined with standard chemotherapy followed by chemoradiation for locally advanced cervical cancer. The goal is to see if this combination works better than current treatments.
This Phase 2 trial tests cadonilimab (an immunotherapy medicine) combined with anlotinib (a targeted drug) for advanced or recurrent cervical cancer that has already been treated. It may help shrink tumors or slow cancer growth, especially if the cancer has a measurable area doctors can track.
This trial tests a new immunotherapy drug called cadonilimab (AK104) combined with standard chemotherapy for women whose small cell neuroendocrine cervical cancer has returned or spread. The goal is to see if this combination helps shrink tumors or slow the cancer better than chemotherapy alone.
Hear when a new Locally Advanced Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.